MA27845A1 - Composition pharmaceutique a teneur en lactate et utilisations de ladite composition - Google Patents

Composition pharmaceutique a teneur en lactate et utilisations de ladite composition

Info

Publication number
MA27845A1
MA27845A1 MA28632A MA28632A MA27845A1 MA 27845 A1 MA27845 A1 MA 27845A1 MA 28632 A MA28632 A MA 28632A MA 28632 A MA28632 A MA 28632A MA 27845 A1 MA27845 A1 MA 27845A1
Authority
MA
Morocco
Prior art keywords
lactate
pharmaceutical composition
per liter
millimoles per
containing pharmaceutical
Prior art date
Application number
MA28632A
Other languages
English (en)
Inventor
Xavier M Leverve
Mustafa Iqbal
Original Assignee
Innogene Kalbiotech Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogene Kalbiotech Pte Ltd filed Critical Innogene Kalbiotech Pte Ltd
Publication of MA27845A1 publication Critical patent/MA27845A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Surgery (AREA)

Abstract

L'invention concerne une composition pharmaceutique contenant 250 à 2 400 millimoles par litre de lactate ou d'acide lactique, 2 à 10 millimoles par litre de cation potassium et éventuellement 2 à 5 millimoles par litre de cation calcium. Ladite invention concerne également des utilisations pharmaceutiques de cette composition ainsi que des utilisations pharmaceutiques d'une composition présentant une concentration de lactate ou d'acide lactique comprise entre 250 et 2 400 millimoles par litre.
MA28632A 2003-05-01 2005-12-01 Composition pharmaceutique a teneur en lactate et utilisations de ladite composition MA27845A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ID20030213 2003-05-01

Publications (1)

Publication Number Publication Date
MA27845A1 true MA27845A1 (fr) 2006-04-03

Family

ID=33397627

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28632A MA27845A1 (fr) 2003-05-01 2005-12-01 Composition pharmaceutique a teneur en lactate et utilisations de ladite composition

Country Status (31)

Country Link
US (1) US20080125488A1 (fr)
EP (2) EP1759695A1 (fr)
JP (1) JP5037937B2 (fr)
KR (1) KR101076059B1 (fr)
CN (1) CN1777416B (fr)
AR (1) AR043670A1 (fr)
AT (1) ATE340568T1 (fr)
AU (1) AU2004233904B2 (fr)
BR (1) BRPI0409867A (fr)
CA (1) CA2523740C (fr)
CY (1) CY1105880T1 (fr)
DE (1) DE602004002585T2 (fr)
DK (1) DK1617834T3 (fr)
EA (2) EA013846B1 (fr)
ES (1) ES2274438T3 (fr)
HK (1) HK1085942A1 (fr)
IL (1) IL171721A (fr)
MA (1) MA27845A1 (fr)
MX (1) MXPA05011532A (fr)
MY (1) MY140382A (fr)
NO (1) NO20055652L (fr)
NZ (1) NZ543201A (fr)
PL (1) PL1617834T3 (fr)
PT (1) PT1617834E (fr)
SG (1) SG160217A1 (fr)
SI (1) SI1617834T1 (fr)
TN (1) TNSN05275A1 (fr)
TW (1) TWI290045B (fr)
UA (1) UA86937C2 (fr)
WO (1) WO2004096204A1 (fr)
ZA (1) ZA200509684B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090285909A1 (en) * 2006-04-03 2009-11-19 Leverve Xavier M Lactate and Calcium Containing Pharmaceutical Composition and Uses Thereof
DK2142186T3 (da) 2007-03-30 2014-08-04 Laccure Ab Anvendelse af oligomerer af mælkesyre ved behandling af gynækologiske infektioner
KR101639098B1 (ko) 2009-03-26 2016-07-12 풀매트릭스 오퍼레이팅 컴퍼니, 인크 폐 질환 치료용 건조 분말 제형 및 방법
CN102448439A (zh) * 2009-03-26 2012-05-09 普马特里克斯公司 用于改变黏膜内衬的生物物理特性的柠檬酸钙及乳酸钙调配物
EP2448571B1 (fr) 2010-08-30 2013-06-12 Pulmatrix, Inc. Poudre sèche respirable contenant du lactate de sodium, du chlorure de sodium et de la leucine
CN105640925B (zh) 2010-08-30 2019-08-16 普马特里克斯营业公司 干燥粉末配方及用于治疗肺部疾病的方法
DK3470057T3 (da) 2010-09-29 2021-11-22 Pulmatrix Operating Co Inc Kationiske tørpulvere omfattende magnesiumsalt
MX354828B (es) 2010-09-29 2018-03-22 Pulmatrix Operating Co Inc Polvos secos de cationes metálicos monovalentes para inhalación.
ES2396650B2 (es) * 2011-07-21 2013-07-16 Universidad Complutense De Madrid Uso de una composición en la elaboración de una solución de diálisis para el tratamiento de las enfermedades cerebrovasculares mediante diálisis peritoneal.
AU2013225982B2 (en) 2012-02-29 2017-11-30 Pulmatrix, Inc. Inhalable dry powders
EP2846787B1 (fr) 2012-05-08 2018-08-29 Aeromics, Inc. Composés pour le traitement de maladies à médiation par l'aquaporine
EP2879524B1 (fr) * 2012-08-01 2016-09-07 Purac Biochem bv Poudre de lactate et son procédé de préparation
US9897609B2 (en) 2012-10-25 2018-02-20 Run Them Sweet, LLC Systems and apparatus to estimate nutritional needs of human and other patients and to support such nutritional needs
US9232815B2 (en) 2012-10-25 2016-01-12 Run Them Sweet, LLC Blood lactate range targets and nutritional formulations and protocols to support patients
US9808031B2 (en) 2012-10-25 2017-11-07 Run Them Sweet Llc Systems and methods to estimate nutritional needs of human and other patients
EP2754356A1 (fr) 2013-01-15 2014-07-16 Purac Biochem N.V. Procédé de production de nisine amélioré
EP2769630B1 (fr) 2013-02-26 2016-04-27 Purac Biochem N.V. Procédé de production de nisine amélioré
JP6473738B2 (ja) 2013-04-01 2019-02-20 パルマトリックス，インコーポレイテッド チオトロピウム乾燥粉末
US9949991B2 (en) 2013-11-06 2018-04-24 Aeromics, Inc. Methods of treating aquaporin-mediated conditions
WO2015182815A1 (fr) * 2014-05-26 2015-12-03 한국생명공학연구원 Composition pharmaceutique pour la prévention et le traitement d'une maladie ischémique, contenant un promoteur de l'expression ou l'activité de ndrg3 en tant que substance active
CN109414036A (zh) 2016-07-07 2019-03-01 帝斯曼知识产权资产管理有限公司 获得油菜籽蛋白质分离物的方法以及由此获得的蛋白质分离物
US10124021B2 (en) * 2016-12-23 2018-11-13 Andrew L. Gostine Intravenous fluid
WO2020163654A1 (fr) * 2019-02-06 2020-08-13 Paul Leo Mcgrane Greffes vasculaires biologiquement modifiées pour des résultats de chirurgie de dérivation améliorés
EP4093507A4 (fr) * 2020-01-24 2024-02-28 Daniel Q Barkey Compositions et procédés de perte de poids
WO2023114375A2 (fr) * 2021-12-16 2023-06-22 Alveolus Bio, Inc. Compositions d'acide lactique inhalables ou ingérables pour traitement d'une maladie pulmonaire chronique

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6776887A (en) * 1985-12-18 1987-07-15 Veech, R.L. Fluid therapy with l-lactate and/or pyruvate anions
EP0441119A3 (en) * 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
US5248507A (en) * 1991-05-31 1993-09-28 Board Of Regents, The University Of Texas System Hypertonic isochloremic formulation for circulatory shock
JPH05255092A (ja) * 1992-03-17 1993-10-05 Kyowa Hakko Kogyo Co Ltd 腸管洗浄用組成物
AU681675B2 (en) * 1993-06-04 1997-09-04 Biotime, Inc. Plasma-like solution
US6306828B1 (en) * 1995-04-06 2001-10-23 Baxter International, Inc. Enantiomerically-enhanced nutritional energy substrates
JPH0940554A (ja) * 1995-08-03 1997-02-10 Nissho Corp グルタミンを含む輸液及びその製造方法
WO1998008500A1 (fr) * 1996-08-26 1998-03-05 Board Of Regents, The University Of Texas System Compositions hypertoniques d'arginine et procedes
US6436444B1 (en) * 1997-09-26 2002-08-20 Ecolab Inc. Acidic aqueous chlorite teat dip providing shelf life sanitizing capacity and tissue protection
CN1068778C (zh) * 1998-05-15 2001-07-25 赵超英 救治用的药物组合物及其制备方法
RU2136293C1 (ru) * 1998-08-04 1999-09-10 Открытое акционерное общество "Биохимик" Способ получения заменителя плазмы крови

Also Published As

Publication number Publication date
SG160217A1 (en) 2010-04-29
SI1617834T1 (sl) 2007-02-28
AR043670A1 (es) 2005-08-03
CA2523740A1 (fr) 2004-11-11
BRPI0409867A (pt) 2006-05-16
TWI290045B (en) 2007-11-21
US20080125488A1 (en) 2008-05-29
ES2274438T3 (es) 2007-05-16
NZ543201A (en) 2007-05-31
IL171721A (en) 2012-05-31
CN1777416A (zh) 2006-05-24
EA010948B1 (ru) 2008-12-30
EP1617834A1 (fr) 2006-01-25
UA86937C2 (ru) 2009-06-10
JP5037937B2 (ja) 2012-10-03
DK1617834T3 (da) 2007-02-05
JP2006525324A (ja) 2006-11-09
MY140382A (en) 2009-12-31
MXPA05011532A (es) 2006-05-31
EP1617834B1 (fr) 2006-09-27
EA200801073A1 (ru) 2008-08-29
KR101076059B1 (ko) 2011-10-21
NO20055652D0 (no) 2005-11-30
ZA200509684B (en) 2007-03-28
PL1617834T3 (pl) 2007-02-28
ATE340568T1 (de) 2006-10-15
CA2523740C (fr) 2012-05-15
CN1777416B (zh) 2012-11-07
DE602004002585T2 (de) 2007-10-25
KR20050119701A (ko) 2005-12-21
NO20055652L (no) 2006-02-01
AU2004233904B2 (en) 2009-11-12
HK1085942A1 (en) 2006-09-08
EP1759695A1 (fr) 2007-03-07
EA200501675A1 (ru) 2006-06-30
AU2004233904A1 (en) 2004-11-11
CY1105880T1 (el) 2011-02-02
TNSN05275A1 (en) 2007-07-10
PT1617834E (pt) 2007-01-31
DE602004002585D1 (de) 2006-11-09
EA013846B1 (ru) 2010-08-30
WO2004096204A1 (fr) 2004-11-11
TW200423923A (en) 2004-11-16

Similar Documents

Publication Publication Date Title
MA27845A1 (fr) Composition pharmaceutique a teneur en lactate et utilisations de ladite composition
MA29856B1 (fr) Derives de diacylindazole en tant qu'inhibiteurs de lipases et de phospholipases
MA27509A1 (fr) Formulations a liberation prolongee contenant de la lamotrigine
CY1117346T1 (el) Κυτταρα που συνεκφραζουν μια σουλφαταση και ενα ενζυμο παραγωγης c-φορμυλογλυκινης και μεθοδοι και χρησεις αυτων
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
TNSN01009A1 (fr) (+) - 6 - [amino - (6 - chloro - pyridine - 3 - yl) - (3 - methyl - 3h - imidazole - 4 - yl) - methyl ] - 4 - ( 3 - chloro-phenyl) -1- cyclopropylmethyl - 1h - quinoleine - 2 - one, procede pour sa preparation et composition la contenant
MA32887B1 (fr) Aminotetrahydropyranes en tant qu'inhibiteurs de dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete
BRPI0519265A2 (pt) composiÇÕes incluindo ferro
BR0313670A (pt) Composição ácida para limpeza pesada de superfìcies
PE20050128A1 (es) Formulacion farmaceutica
FR2869803A1 (fr) Particules activables, preparation et utilisations
BRPI0504445A (pt) composição de trombina e processo para a sua preparação
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
BR0110145A (pt) Método e composição para limpar instrumentos médicos
BR0312407A (pt) Fenilbenzamidas
MA27670A1 (fr) Composition pharmaceutique contenant de l'acide 5-methyl-2-2'-(chloro-6'-fluoroanilino)phenylacetique
BR9810520A (pt) Inibidor do fator xa isolado ou em combinação com um anti-agregador plaquetário, contra a trambose arterial
BRPI0519406A2 (pt) manoproteÍna com solubilidade integral em vinho e sua aplicaÇço na estabilizaÇço de vinho
BRPI0416534A (pt) composições multiparticuladas com estabilidade melhorada
Jhala et al. Mitigating effects of some antidotes on fluoride and arsenic induced free radical toxicity in mice ovary
ATE406903T1 (de) Zusammensetzung und ihre verwendungszwecke zur bekämpfung von kater
MA29784B1 (fr) Combinaisons contenant dmxaa pour traiter le cancer
TR200302296T4 (tr) 20 ppm klor iyonundan daha çok ihtiva eden kararlı gabapentin
MA31611B1 (fr) Nouveaux tetrahydronaphtalenes substitues leurs procedes de preparation et leur utilisation en tant que medicaments
BRPI0409866A (pt) processo para a preparação de (4-hidroxi-6-oxo-tetrahidropiran-2-il) acetonitrila e seus derivados